A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer. (3rd July 2017)

• Record Type: Journal Article
• Authors: Bendell, Johanna C.; Joseph, Mathew; Barnes, Kirk; Mainwaring, Mark; Shipley, Dianna; Reddy, Chandra; Blakely, Laura; Blachly, Ronald; Lane, Cassie M.; Earwood, Chris; Kuzur, Michel
• Is Part Of: Cancer investigation. Volume 35:Number 6(2017)
• Page Start: 386
• Page End: 392
• Publication Date: 2017-07-03
• Subjects: Axitinib -- maintenance -- colorectal cancer; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2017.1310221
• Languages: English
• ISSNs: 0735-7907

Abstract

ABSTRACT: This phase-2 trial evaluated the efficacy of axitinib as maintenance therapy for patients with metastatic colorectal cancer (mCRC) following first-line treatment with FOLFOX/bevacizumab. Patients with mCRC received mFOLFOX/bevacizumab followed by axitinib maintenance after four cycles. The primary endpoint was progression-free survival (PFS). Seventy patients were enrolled. Common treatment-related toxicities were fatigue, nausea, diarrhea, and peripheral neuropathy during FOLFOX/bevacizumab treatment; and fatigue, hypertension, diarrhea, and peripheral neuropathy during axitinib treatment. Median PFS was 8.3 months. Treatment with FOLFOX/bevacizumab followed by maintenance axitinib as first-line treatment for mCRC produced a median PFS consistent with historical controls of other first-line regimens.